We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ZOLGENSMA IT Novartis Pharmaceuticals Australia Pty Ltd
Product name
ZOLGENSMA IT
Accepted date
Sep-2025
Active ingredients
onasemnogene abeparvovec
Proposed indication
Zolgensma IT (onasemnogene abeparvovec) is an adeno-associated virus (AAV) vector-based gene therapy that is proposed for the treatment of spinal muscular atrophy (SMA) in patients 2 years of age and older.
Application type
C (new indication)
Publication date
Sep-2025